Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2021 Annual Meeting of Stockholders held on June 16, 2021. Trevi Therapeutics, Inc. is a Delaware corporation with its principal executive offices in New Haven, Connecticut. The company is registered on The Nasdaq Stock Market LLC under the symbol TRVI and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on two primary proposals at the annual meeting:
- Election of Directors: Three nominees were elected as Class II directors for terms expiring at the 2024 annual meeting.
- Dominick Colangelo: 13,943,000 For; 165,599 Withheld; 2,148,323 Broker Non-Votes.
- Edward Mathers: 13,905,573 For; 203,026 Withheld; 2,148,323 Broker Non-Votes.
- David Meeker, M.D.: 13,871,141 For; 237,458 Withheld; 2,148,323 Broker Non-Votes.
- Ratification of Auditors: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.
- For: 16,205,748
- Against: 731
- Abstain: 50,443
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the results of the shareholder vote.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the election of the three Class II directors.
- Confirm the engagement of Ernst & Young LLP as the independent auditor for the 2021 fiscal year.
- Note the significant number of broker non-votes (2,148,323) recorded for the director elections, which may indicate beneficial ownership held in street name.